We prospectively studied agreement in haemoglobin estimation between two point-of-care devices (Pronto-7 ® Pulse CO-Oximetry™, Masimo Corporation, Irvine, California, USA and HemoCue ® Hb 201+, HemoCue, Angelholm, Sweden) and an automated laboratory analyser (Sysmex XE5000, Sysmex Corporation, Kobe, Japan). Venous blood sampling and finger co-oximeter readings were performed on 141 pregnant women undergoing routine mid-trimester haemoglobin assessment. Three replicate measures were performed and analysis used Bayesian-based variance component modelling to provide estimates of repeatability, between person within method bias and precision. Repeatability, assessed by coefficient of variation, was higher for Pronto-7 ® (2.3%) compared to HemoCue ® (5.2%). Fixed bias (mean difference, device -laboratory) was +1.18 (standard deviation 1.19) g/dl and -0.01 (standard deviation 1.34) g/dl for Pronto-7 ® and HemoCue ® respectively, with no statistical evidence of proportional bias. Based upon a single device reading, the 95% prediction limits for Pronto-7 ® were -1.2 to 3.6 g.dl-1 and HemoCue ® were -2.7 to 2.7 g/dl. For both devices precision was not meaningfully improved by averaging replicate readings. However, repeated readings may allow detection of aberrant results. Overall both devices are imprecise and 95% prediction limits wide. We present further prediction limits, derived from the posterior distribution and adjusted for any fixed bias for set levels of probability (certainty). These may be used to support clinical decisions when using these point-of-care devices.
Laboratory measurement of total haemoglobin concentration is determined by automated pathology devices using cyanide or cyanide-free sodium lauryl sulphate chemical conversion of all haemoglobin moieties to cyano-or lauryl-methaemoglobin, followed by absorption photometry. The procedure requires both a sample of blood and transport to the laboratory. Two point-of-care methods, which claim to provide an accurate estimate of haemoglobin concentration in less than one minute, are absorbance photometry (HemoCue ® Hb 201+; HemoCue, Angelholm, Sweden) and non-invasive spectrophotometry (Pulse CO-Oximetry TM ; Masimo Corporation, Irvine, California, USA). The HemoCue ® Hb 201+ device requires a sample of blood and uses azide chemical conversion of haemoglobin to azidemethaemoglobin followed by absorbance photometry at two wavelengths (570 and 880 nm) to measure total haemoglobin concentration, similar to that described above for laboratory determination. Pulse CO-Oximetry TM , with either the continuous reading Rad-7 or the intermittent Pronto-7 ® , is a non-invasive method using light absorbance at more than seven separate wavelengths to estimate total haemoglobin concentration by a transcutaneous finger probe. The two devices use different algorithms and only the Rad-7 provides estimates of carboxy-and methaemoglobin moieties 1 . Laboratory co-oximeters (standard automated blood gas analysers) use similar absorbance principles. All methods measure total (oxy, carboxy and methoxy) haemoglobin concentration.
We conducted a method comparison study of haemoglobin measured by two point-of-care devices (Pronto 7 ® and HemoCue ® Hb 201+), and an automated laboratory analyser. The research questions posed were: "what is the repeatability of each measurement method within patient/ method?", "is there fixed and/or proportional bias in haemoglobin estimation between each of the non-invasive techniques and that performed by a laboratory-based automated analyser?" and "what Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 is the mean difference and 95% prediction intervals for the laboratory haemoglobin given either a single reading or using the mean of three readings for each device?".
MATERIAL AND METHODS
The study was approved by the local Human Research Ethics Committee, was prospectively registered with ANZCTR, ACTRN 12612000679886, 25 March 2012 and all participants gave written informed consent. A convenience sample of pregnant women, undergoing week 20 blood tests (glucose tolerance test and full blood examination) as part of their routine antenatal care were approached to enrol in this study. We excluded non-English speaking patients, patients who were identified as Jehovah's Witnesses and those wearing artificial nails or polish.
At the time of venous blood sampling for routine antenatal blood tests, an additional 4 ml of blood was placed into a tube containing K 2 EDTA powder, immediately agitated and, within one hour, the blood was used to load three cuvettes to obtain haemoglobin estimates using the HemoCue ® Hb 201+ device. The HemoCue ® Hb 201+ is factorycalibrated and performs a self-test at start up. The cuvettes used were in-date and stored according to manufacturer's instructions. The percutaneous haemoglobin estimation was obtained by placing the Pronto-7 ® non-invasive transcutaneous probe (4D, software version 2.2.15) on the non-dominant ring finger and, if adequate signal strength was obtained, three sequential readings 60 seconds apart were obtained. All readings were performed by one nurse practitioner blinded to laboratory haemoglobin but not to readings from the two point-of-care devices. Logistics did not allow for blinded readings of the three replicates per point-of-care device nor between devices. Instructions were that only three readings were to be obtained from each device, that each reading was to be accurately recorded and that no individual reading should be repeated or altered under any circumstances. Failure of each test was recorded as such. Laboratory analysis of the routine blood sample was performed using an XE5000-Hematology analyser (Sysmex Corporation, Kobe, Japan) and underwent routine calibration as required for laboratory accreditation.
Data
Each patient is represented by seven haemoglobin readings; the three replicate measurements on each patient by HemoCue ® Hb 201+ and Masimo Pronto-7 ® devices and one measurement made in the laboratory by the XE5000-Hematology analyser. Patient characteristics and raw haemoglobin measurements are presented as mean, standard deviation (SD), minimum and maximum values.
Statistical methods
In this study, the true underlying but unknown participant haemoglobin was considered to remain stable over the measurement period. As such, the within-subject replicate measurements are assumed to be exchangeable (replicates from either device can be arbitrarily reordered for that device and can thus can be paired with any measurement from the other device). The relationships between the three methods of measurement were assessed by fitting general variance components models to the haemoglobin measurements, as described in Chapter 7 of Carstensen 2 . These models were fitted using a Markov chain Monte Carlo (MCMC) estimation in a Bayesian setting in the function multiple chain Markov chain Monte Carlo (MCmcmc) from the MethComp package 3 for R 4 . A full account of the analysis, including conversion equations, is available at http://BendixCarstensen.com/MethComp/Projects/ Hb/Hiscock.pdf. The model asserts that the mean measurements made by the different methods are linearly related and is an extension of the model implied by the familiar Bland-Altman procedure. This method derives 95% "limits of agreement" (a prediction interval for the difference between measurements from different methods) where it is assumed that the mean measurements from two methods (for a given true underlying measurement) differ only by a constant. Two random effects variance components were estimated, one representing random variation of measurements between individuals within each of the methods and the other representing the 'pure' measurement error or random variation within individual within methods, so both variance components refer to variations within methods. Given only one measurement per patient by the laboratory method, its two variance components cannot be separated and estimated independently. This multilevel Bayesian approach takes account of replicate measures and the resulting posterior distribution provides both posterior median and probability determined credible (prediction) intervals. In addition to the standard 95% prediction interval, we present additional intervals where the probability that the device-laboratory difference within the limit boundaries is set at 90%, 80% and 50%. Withinpatient/method variability was also assessed using the coefficient of repeatability, calculated as 2.83 times the within-patient SD for each device, the upper limit of a 95% prediction interval for the difference between repeated measurements using the same device 5 . Sensitivity analysis using mean values of the three replicate readings for each device within individuals was also performed, as this provides a valid 95% prediction interval for practitioners who always take the average of three replicate values.
RESULTS
One hundred and forty-one pregnant women were recruited for the study over a ten week period in 2012. Patient characteristics and haemoglobin values for all methods and replicates are presented in Table  1 . Mean laboratory haemoglobin was 12.0 g/dl with values from 9.7 to 15.2 g/dl. One subject (laboratory = 13.5 g/dl) had values 7.4, 18.8 and 5.0 g/dl for the HemoCue ® replicates and, whilst there was no known testing fault or data entry error, at least one of these values is clearly incorrect and this patient was excluded from the analysis. Based upon our fitted model, for the log-transformed data, we found a within subject SD of 0.61 g/dl and 0.27 g/dl and within subject coefficient of variation of 5.2% and 2.3% for HemoCue ® and Pronto-7 ® devices respectively ( Table 2) .
Calculated coefficients of repeatability were 0.82 and 1.70 g/dl for Pronto-7 ® and HemoCue ® devices respectively. For replicate readings using the Pronto-7 ® , there were no subjects with values more than 3 g/dl and two (1.4%) subjects who had at least one value more than 2 g/dl but less than 3 g/dl different from the other replicates. For the HemoCue ® method, four (2.9%) subjects had at least one reading more than 3g/dl and a further five (3.6%) subjects had at least one value more than 2 g/dl but less than 3 g/dl different from the other replicates. Due to the relatively narrow range of the haemoglobin values in this study (laboratory 9.7 to 15.2 g/dl), the slopes of the conversion equations when a linear relationship between methods is assumed were estimated imprecisely and there was no strong statistical evidence of proportional bias (slope different from one). We therefore report the results from the simpler model assuming a constant bias. For completeness, the conversion equations from the general linear model are presented in the report referenced above. Figures 1 and 2 show the Bland-Altman plots of the difference (device-laboratory) for all readings, along with the median bias and a 95% prediction interval based upon the MCmcmc model, assuming constant bias for HemoCue ® and Pronto-7 ® devices respective. Compared to laboratory haemoglobin, the HemoCue ® estimate was 0.01 (SD 1.34) g/dl smaller, with 95% prediction limits from -2.7 to 2.7 g/dl, whilst the Pronto-7 ® device was 1.18 (SD 1.19) g/dl higher than laboratory, with 95% prediction limits from -1.2 to 3.6 g/dl. If the mean of three replicate values is used, then the median bias is unchanged and the SD of the difference is reduced, associated 95% prediction limits for the HemoCue ® were -2.5 to 2.5 g/dl (reduction of 8%) and for the Pronto-7 ® device were -1.1 to 3.5 g/dl (reduction of 4%). We also present prediction limits, derived from the posterior distribution, at the following set probability levels: 90%, 80%, 60% and 50% (Table 3 ).
DISCUSSION
We found that the Pronto-7 ® device showed substantially better repeatability compared to the HemoCue ® Hb 201+ device. Under stable conditions, we would be 95% certain that a repeat haemoglobin measurement using the Pronto-7 ® co-oximeter would lie within 0.82 g/dl of the previous reading, compared to 1.7 g/dl for the HemoCue ® 201+. For both devices, manufacturer instructions were followed in order to minimise recording variability and further, in this study all readings were performed by a single operator. Using an in vitro assay study, Rippmann et al 6 found that the HemoCue ® cuvette accounted for 68% of this within-sample variability. The use of mean haemoglobin, calculated over the three replicates, reduces the SD of the difference by only 8% and 4% for HemoCue ® and Pronto-7 ® devices respectively, resulting in only slightly narrower 95% prediction limits for both devices. Consequently, the approach of averaging three replicate values has little advantage, apart from alerting the user to a clearly aberrant reading.
Our results indicate that the HemoCue ® Hb 201+ was unbiased (haemoglobin difference 0.0 g/dl), but that there was an important magnitude of bias for the Pronto-7 ® pulse co-oximeter, which over-read the laboratory haemoglobin by 1.2 g/dl on average. Our HemoCue ® Hb 201+ results are consistent with other method comparison studies performed using arterial or venous blood that found fixed bias ranging from -0.17 to 0.3 g/dl [7] [8] [9] [10] . Our Pronto-7 ® median bias is higher than four other studies so far published, where the mean difference ranged from -0.53 g/dl to 0.2 g/ dl [11] [12] [13] [14] , but similar to the results in some method comparison studies comparing the continuous reading Rad-7 device with a laboratory analyser, which found the median bias ranging from 0.9 to 1.2 g/dl [15] [16] [17] . Given that all these studies followed the manufacturer's recommendations, this may reflect variability in device performance under clinical conditions. Both devices have a similar magnitude of precision, with the SD for a future prediction of the laboratory haemoglobin, based upon a single device reading, being 1.19 g/dl and 1.34 g/dl for Pronto-7 ® and HemoCue ® devices respectively. This translates to slightly wider 95% prediction limits for the HemoCue ® device. Again, our findings are consistent with previous studies with an SD of difference between 1.00 to 1.04 g/dl and 0.67 to 1.30 g/dl for Pronto-7 ®11, 12 and HemoCue ®7-10 respectively.
A major limitation of our study is the range and distribution of true underlying haemoglobin values. Increasing both the range of true haemoglobin values and the number of observations at these extremes increases the precision of regression coefficients and improves the ability to distinguish between constant and proportional bias. The availability of sufficient patients with low and high haemoglobins limits assessment of bias in clinical studies using both technologies. Using in vitro serial dilution assay techniques, Rippman et al 6 showed that the HemoCue ® (unknown model) exhibited a linear response down to the lowest laboratory haemoglobin studied at 2 g/dl. However, formal assessment for proportional bias was not performed in this study.
Many practitioners use capillary blood to load HemoCue ® cuvettes. Even when following the detailed manufacturer guidelines regarding capillary sampling technique, the use of capillary blood samples may result in a fall in precision compared to sampling from venous or arterial sites, with the SD of difference increasing by about 0.25 g/dl 18 . This would further inflate the prediction limits found in our study. Both software and hardware updates may lead to changes in device performance (bias and precision) and this caveat particularly applies to the emerging pulse co-oximetry technology first introduced in 2008. The HemoCue ® absorption photometry technology appears to have remained largely unchanged since 2002, when self-calibration was incorporated into the 201+ model. Further method comparison studies may need to be undertaken.
The potential clinical use of these point-of-care devices is dependent on clinical circumstance and may be considered in three broad scenarios. Firstly, in the acute severe bleeding patient, it is likely that blood transfusion will be based upon the clinical assessment with further management using laboratory-based analysis. It is in the subacute bleeding patient (whilst awaiting the results of laboratory analysis) and in the stable pre and postoperative patient (instead of using laboratory analysis) that these technologies may find clinical application in place of laboratory analysis. Morey et al 19 have proposed the use of haemoglobin error grid analysis to focus attention on the effect not only of device bias, but also, more importantly, device precision 20 on patient treatment decisions. They argue that major errors in management may occur if the device reading is less than 6 g/dl when the laboratory is greater than 10 g/dl and vice versa. Given the range of our study's laboratory haemoglobin (> 9.7 g/dl), our results apply only to the former scenario. We present prediction limits, derived from the posterior distribution, and adjusted for any fixed bias for set levels of probability (certainty). These may be used to support clinical decisions based upon these technologies. For example, if we accept 80% certainty, then these limits reduce to -1.7 to 1.7 g/dl and -0.4 to 2.7 g/dl for HemoCue ® and Pronto-7 ® devices.
Currently, neither device can replace laboratorybased haemoglobin analysis. The HemoCue ® 201+ is unbiased. However, it has poor within-patient repeatability and low precision, which could be worse if capillary sampling is used. The Masimo Pronto-7 ® pulse co-oximeter does not require blood sampling and has slightly improved precision compared to the HemoCue ® 201+, but has a greater bias, which must be accounted for when interpreting readings (on average, overestimating laboratory haemoglobin by 1.2 g/dl).
